Please select the option that best describes you:

Would you consider enfortumab vedotin + pembrolizumab prior to surgery for a patient with urothelial carcinoma with regional nodes who is not eligible for neoadjuvant cisplatin?   

This would be for the "locally advanced unresectable" indication. Consider an older patient who is not eligible for NAC nor TMT due to nodal disease and patient related factors.



Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Community Practice